S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Forecast, Price & News

$4.49
+0.07 (+1.58%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.41
$4.78
50-Day Range
$2.31
$4.85
52-Week Range
$1.95
$28.75
Volume
124,135 shs
Average Volume
1.46 million shs
Market Capitalization
$53.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3,750.00

Biora Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
83,418.9% Upside
$3,750.00 Price Target
Short Interest
Healthy
3.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.69) to ($4.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

610th out of 983 stocks

Pharmaceutical Preparations Industry

302nd out of 486 stocks


BIOR stock logo

About Biora Therapeutics (NASDAQ:BIOR) Stock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BIOR Stock News Headlines

⚡ 2,467% Return on Israeli Laser Company?
This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.
Q1 2023 Biora Therapeutics Inc Earnings Call
⚡ 2,467% Return on Israeli Laser Company?
This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.
Earnings Preview: Biora Therapeutics
Earnings Preview For Biora Therapeutics
See More Headlines

BIOR Price History

BIOR Company Calendar

Today
6/02/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOR
Fax
N/A
Employees
642
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3,750.00
High Stock Price Forecast
$3,750.00
Low Stock Price Forecast
$3,750.00
Forecasted Upside/Downside
+82,317.6%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-38,160,000.00
Net Margins
-20,895.00%
Pretax Margin
-26,100.50%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($8.85) per share

Miscellaneous

Free Float
8,154,000
Market Cap
$53.96 million
Optionable
Optionable
Beta
1.16

Key Executives

  • Mr. Aditya P. Mohanty M.B.A. (Age 56)
    CEO & Director
    Comp: $383.76k
  • Mr. Eric d'Esparbes (Age 55)
    Chief Financial Officer
    Comp: $619.3k
  • Mr. Clarke Neumann J.D. (Age 59)
    Gen. Counsel & Sec.
    Comp: $712.02k
  • Eric Fox
    VP of Fin. & Accounting & Treasurer
  • Mr. Troy Seelye (Age 59)
    Chief Information Officer
  • Mr. George Gianakopoulos (Age 62)
    Sr. VP of Sales
  • Ms. Robyn Hatton
    Head of HR
  • Mr. Kevin Howe Ph.D.
    Sr. VP of Strategic Operations
  • Dr. Sharat Singh Ph.D. (Age 64)
    Head of Research
  • Dr. Paul Shabram M.B.A.
    Head of Technical Operations













BIOR Stock - Frequently Asked Questions

What is Biora Therapeutics' stock price forecast for 2023?

0 equities research analysts have issued 1 year target prices for Biora Therapeutics' shares. Their BIOR share price forecasts range from $3,750.00 to $3,750.00. On average, they expect the company's share price to reach $3,750.00 in the next twelve months. This suggests a possible upside of 82,317.6% from the stock's current price.
View analysts price targets for BIOR
or view top-rated stocks among Wall Street analysts.

How have BIOR shares performed in 2023?

Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR stock has decreased by 94.5% and is now trading at $4.55.
View the best growth stocks for 2023 here
.

Are investors shorting Biora Therapeutics?

Biora Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 390,700 shares, a drop of 7.7% from the April 30th total of 423,100 shares. Based on an average daily trading volume, of 142,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.5% of the shares of the company are sold short.
View Biora Therapeutics' Short Interest
.

When is Biora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BIOR earnings forecast
.

When did Biora Therapeutics' stock split?

Biora Therapeutics shares reverse split on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Biora Therapeutics' stock symbol?

Biora Therapeutics trades on the NASDAQ under the ticker symbol "BIOR."

Who are Biora Therapeutics' major shareholders?

Biora Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.55%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.37%), Schonfeld Strategic Advisors LLC (0.36%), Susquehanna International Group LLP (0.00%) and Group One Trading L.P. (0.00%).
View institutional ownership trends
.

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biora Therapeutics' stock price today?

One share of BIOR stock can currently be purchased for approximately $4.55.

How much money does Biora Therapeutics make?

Biora Therapeutics (NASDAQ:BIOR) has a market capitalization of $53.96 million and generates $310,000.00 in revenue each year. The company earns $-38,160,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis.

How many employees does Biora Therapeutics have?

The company employs 642 workers across the globe.

How can I contact Biora Therapeutics?

Biora Therapeutics' mailing address is 4330 La Jolla Village Dr Ste 200, San Diego, California 92122. The official website for the company is www.bioratherapeutics.com. The company can be reached via phone at 833-727-2841 or via email at ir@progenity.com.

This page (NASDAQ:BIOR) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -